Aurobindo Pharma share news, announcements and annual reports
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,644.80up ₹17.30 (1.06%)BSE ₹1,640.10
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,627.50.
28 Oct: open ₹1,625.00, high ₹1,650.00, low ₹1,609.10
52-week range of traded prices to 28 Oct 2026
₹1,081.40Low, 28 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹94,638 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.49
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,54,48548.5% delivered
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 34 of 34.
Jul 2007
2 Jul · Business
Press release dated June 30, 2007, titled "Aurobindo records revenues of Rs.23 billions with multifold growth in earnings". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Dividend
Board at its meeting held on June 30, 2007, has recommended a dividend of 50% (Rs.2.50 per share of Rs.5/- each) on its equity share capital of the Company for the year 2006-07 subject to approval of members in the general meeting.1 Jul · Results
Standalone Results for the quarter ended on 31-MAR-2007 as follows: Net Sales of Rs. 53276 lacs for quarter ending on 31-MAR-2007 against Rs. 46304 lacs for the quarter ending on 31-MAR-2006. Net Profit / (Loss) of Rs. 7811 lacs for the quarter ending on 31-MAR-2007 against Rs. 3753 lacs for the quarter ending on 31-MAR-2006.1 Jul · Results
Consolidated Results for the year ended on 31-MAR-2007 as follows: Net Sales of Rs. 225022 lacs for year ending on 31-MAR-2007 against Rs. 169550 lacs for the year ending on 31-MAR-2006. Net Profit / (Loss) of Rs. 20096 lacs for the year ending on 31-MAR-2007 against Rs. 6970 lacs for the year ending on 31-MAR-2006.1 Jul · Results
Standalone Results for the year ended on 31-MAR-2007 as follows: Net Sales of Rs. 197972 lacs for year ending on 31-MAR-2007 against Rs. 147220 lacs for the year ending on 31-MAR-2006. Net Profit / (Loss) of Rs. 22908 lacs for the year ending on 31-MAR-2007 against Rs. 6937 lacs for the year ending on 31-MAR-2006.
Jun 2007
26 Jun · Business
The Hon'ble court of Andhra Pradesh has approved the Scheme of Arrangement for the merger of APL Life Sciences Limited (APL Life) and Senor Organics Private Limited (Senor) into Aurobindo Pharma Limited and the utilisation of share premium account of the Company. Further, no shares would be issued by the Company in consideration for the merger as both APL Life and Senor are wholly owned subsidiary companies. KPMG India Private Limited has assisted in the process of merger26 Jun · Business
Press release dated June 26, 2007, titled "Aurobindo receives Tentative approval for Quinapril Hydrochloride and Hydrochlorothiazide Tablets from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jun · Board meeting
To consider among other business, the Audited Financial Results of the Company for the Year ended March 31, 2007 and also to recommend Dividend, if any for the year ended March 31, 2007.19 Jun · Business
Press release dated June 19, 2007, titled "Aurobindo received Zidovudine approval from MCC South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jun · Business
Press release dated June 18, 2007, titled "Aurobindo receives Tenth approval from MCC South Africa". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jun · Business
Press release dated June 15, 2007, titled "Aurobindo gets USFDA Approval for Trandolapril Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jun · Business
Press release dated June 15, 2007, titled "Aurobindo receives USFDA Approval for Cefpodoxime proxetil Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jun · Business
Press release dated June 13, 2007, titled "Aurobindo Pharma Unveils New Corporate Identity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Jun · Business
Press release dated June 05, 2007, titled "Aurobindo receives USFDA approval for its Ciprofloxacin". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Jun · Business
Press release dated June 05, 2007, titled "Aurobindo gets USFDA Approval for its Cefpodoxime oral suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
29 May · Business
Press release dated May 29, 2007, titled "Aurobindo gets USFDA Approval for its Cefprozil Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 May · Business
Press release dated May 07, 2007, titled "Aurobindo receives USFDA approval for its Zolpidem". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 May · Business
Press Release dated May 01, 2007 titled as "Aurobindo receives Ninth approval from MCC South Africa". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
26 Apr · Business
Press release dated April 26, 2007, titled "Aurobindo receives Eighth approval from MCC South Africa". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Apr · Results
We arrange to publish the Audited Financial Results of the Company for the year ended 31st March 2007 on or before 30th June 2007. Therefore, we will not be publishing the Un-Audited Results of the Company for the quarter ended 31st March 20074 Apr · Business
Press release dated April 04, 2007, titled "MEB Netherlands approves Lisinopril Tablets of Aurobindo". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
29 Mar · Business
Press release dated March 29, 2007, titled "Cephazone, cephalosporin sterile injectable facility in California, is approved by USFDA and receives approval of Ceftriaxone from USFDA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Mar · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the three months ended December 31, 2006. The details of Limited review report and the comments of the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). For more details click here.15 Mar · E-mail ID for Investor Complaints
The following is the exclusive e-mail ID of the Company to address the investor grievance/complaints : E-mail ID: investorgrievances@aurobindo.com ; Contact person : A. Mohan Rami Reddy, Company Secretary/Compliance Officer.9 Mar · Business
Press release dated March 09, 2007, titled "Aurobindo receives US FDA Final approval For Didanosine Oral Suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2007
28 Feb · Business
Press release, dated February 28, 2007, titled "Aurobindo receives NAM Finland Approval for its facility at UNIT - VI". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Feb · Business
Press release, dated February 21, 2007, titled "Aurobindo's debut in Botswana is with 9 products in one go". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Feb · Business
The equity shareholders of the Company at their Court Convened Meeting held on February 20, 2007, have approved the Scheme of Arrangement ("the Scheme") for the merger of APL Life Sciences Ltd ("APL Life") and Senor Organics Pvt Ltd ("Senor"), both being wholly owned subsidiaries of the Company, with itself and the utilization of the Securities Premium account pursuant to the provision of Sections 391 to 394 read with Sections 78 and Sections 100 to 103 and other applicable provisions of the Companies Act, 1956 with the requisite majority. The appointed date of the Scheme of Arrangement is April 01, 200620 Feb · Business
Press release dated February 20, 2007, titled "Aurobindo receives seventh approval from MCC South Africa". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Feb · Notice of Meeting
Notice convening the Meeting of the shareholders of the Company on 20.02.2007 pursuant to the directions of the Hon'ble High Court of Andhra Pradesh, Hyderabad, for the purpose of considering the proposed merger of APL Life Sciences and Senor Organics Pvt. Limited with Aurobindo Pharma Limited. A copy of Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Feb · Business
Press release, dated February 02, 2007, titled "Aurobindo's tally of USFDA approved cephs goes up." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
31 Jan · Company's Comments on Audit Qualifications
With regard to addressing the qualifications of audited accounts for the year ended March 31, 2006 in the Quarterly results (a) on treatment of non-compete fee adjusted against the capital reserve, it is to explain that the issue has no impact either on the profit of March 31, 2006 or on any of the quarterly results of the current year and (b) on non-provision for diminution in value of certain investments made in overseas subsidiaries, it is to explain that in the opinion of management, the diminution is of temporary nature and does not require any provision31 Jan · Business
Press release, dated January 31, 2007, titled "Aurobindo Pharma's growth momentum continues. Net Profit, EBITDA, Revenues grew by 130%, 58% & 33% respectively." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Business
Press release dated January 30,2007, titled "Aurobindo receives USFDA nod for its facility at UNIT-VI". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jan · Business
Company had filed a company application with the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad on January 03,2007. Subsequently, the Hon'ble High Court, by an order made on January 05,2007 (order received on January 18,2007) has directed that a meeting of the Equity Shareholders of the Company be convened and held on February 20,2007 for the purpose of considering, and if thought fit, approving with or without modification(s), the Scheme of Arrangement between Aurobindo Pharma Limited and APL Life Sciences Limited and Senor Organics Private Limited and their respective shareholders.29 Jan · Business
Press release dated January 29,2007, titled "Aurobindo bags one more cephalosporin from USFDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”19 Jan · Business
Press release dated January 18, 2007, titled "Aurobindo receives 36th USFDA approval". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Business
Press release dated January 02, 2007, titled "Aurobindo receives two more USFDA approvals". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.